The effects of ellagic acid and other pomegranate (Punica granatum L.) derivatives on human gastric cancer AGS cells
Although surgery with or without (neo)adjuvant chemo/radiotherapy, as the standard treatments, can be suitable therapeutic strategies for gastric cancer, side effects and drug resistance are two main treatment obstacles. It has been discovered that pomegranate and its natural derivatives, especially ellagic acid (EA), offer significant anti-cancer effects while causing trivial side effects. In this study, we aimed to explore the anti-cancer effects of EA on a human gastric adenocarcinoma cell line (AGS) as well as in immunocompromised mice bearing human gastric tumors, for the first time. HPLC was used for determining EA in samples. MTT assay, apoptosis and scratch assay, gelatin zymography, and quantitative RT-PCR were used to determine the anti-cancer properties of different concentrations of pomegranate fruit juice, pomegranate peel extract, and EA. Furthermore, the effects of these compounds were investigated on immunosuppressed C57BL/6 mice carrying human gastric cancer tumors. EA could inhibit the proliferation and migration of gastric cancer cells. It also had significant effects on reducing both expression and activity of MMP-2 and MMP-9. Further, it was demonstrated that with alterations in the expression of genes involved in apoptosis and inflammation including P53, BAX, APAF1, BCL2, iNOS, NF-κB, IL-8, and TNF-α, EA treatment led to increased cancer cell death and reduced inflammation. Furthermore, its use in mice bearing gastric tumors resulted in a significant reduction in tumor volume without any obvious side effects. Ellagic acid exhibited anti-cancer effects on gastric adenocarcinoma, and can be considered as a safe anti-cancer agent for further preclinical studies on this cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Human & experimental toxicology - 41(2022) vom: 18. Jan., Seite 9603271211064534 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheshomi, Hamid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
19YRN3ZS9P |
|---|
| Anmerkungen: |
Date Completed 22.03.2022 Date Revised 22.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/09603271211064534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33711305X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33711305X | ||
| 003 | DE-627 | ||
| 005 | 20231225233654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/09603271211064534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM33711305X | ||
| 035 | |a (NLM)35179410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheshomi, Hamid |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effects of ellagic acid and other pomegranate (Punica granatum L.) derivatives on human gastric cancer AGS cells |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2022 | ||
| 500 | |a Date Revised 22.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Although surgery with or without (neo)adjuvant chemo/radiotherapy, as the standard treatments, can be suitable therapeutic strategies for gastric cancer, side effects and drug resistance are two main treatment obstacles. It has been discovered that pomegranate and its natural derivatives, especially ellagic acid (EA), offer significant anti-cancer effects while causing trivial side effects. In this study, we aimed to explore the anti-cancer effects of EA on a human gastric adenocarcinoma cell line (AGS) as well as in immunocompromised mice bearing human gastric tumors, for the first time. HPLC was used for determining EA in samples. MTT assay, apoptosis and scratch assay, gelatin zymography, and quantitative RT-PCR were used to determine the anti-cancer properties of different concentrations of pomegranate fruit juice, pomegranate peel extract, and EA. Furthermore, the effects of these compounds were investigated on immunosuppressed C57BL/6 mice carrying human gastric cancer tumors. EA could inhibit the proliferation and migration of gastric cancer cells. It also had significant effects on reducing both expression and activity of MMP-2 and MMP-9. Further, it was demonstrated that with alterations in the expression of genes involved in apoptosis and inflammation including P53, BAX, APAF1, BCL2, iNOS, NF-κB, IL-8, and TNF-α, EA treatment led to increased cancer cell death and reduced inflammation. Furthermore, its use in mice bearing gastric tumors resulted in a significant reduction in tumor volume without any obvious side effects. Ellagic acid exhibited anti-cancer effects on gastric adenocarcinoma, and can be considered as a safe anti-cancer agent for further preclinical studies on this cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ellagic acid | |
| 650 | 4 | |a P53 | |
| 650 | 4 | |a Punica granatum | |
| 650 | 4 | |a apoptosis | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a inflammation | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Plant Extracts |2 NLM | |
| 650 | 7 | |a Ellagic Acid |2 NLM | |
| 650 | 7 | |a 19YRN3ZS9P |2 NLM | |
| 700 | 1 | |a Bahrami, Ahmad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Rafatpanah, Houshang |e verfasserin |4 aut | |
| 700 | 1 | |a Matin, Maryam M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human & experimental toxicology |d 1991 |g 41(2022) vom: 18. Jan., Seite 9603271211064534 |w (DE-627)NLM013305239 |x 1477-0903 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g day:18 |g month:01 |g pages:9603271211064534 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/09603271211064534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |b 18 |c 01 |h 9603271211064534 | ||